Exhibit 99.1

Per-Se Technologies Announces Early Termination of HSR Waiting Period for
NDCHealth Corporation Acquisition

    ALPHARETTA, Ga.--(BUSINESS WIRE)--Sept. 29, 2005--Per-Se
Technologies, Inc. (Nasdaq: PSTI) today announced that it has received
notification of early termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 related to its
acquisition of Atlanta-based NDCHealth Corporation (NYSE: NDC).
    As previously announced on August 29, 2005, Per-Se and NDCHealth
entered into a definitive agreement for Per-Se to acquire the
physician, hospital and retail pharmacy businesses of NDCHealth. As
part of the transaction, Wolters Kluwer, based in Amsterdam, the
Netherlands, will purchase the pharmaceutical information management
business from NDCHealth. Also as previously announced, the transaction
is expected to close within three to six months from signing. The
acquisition remains subject to other closing conditions, including
approval by shareholders of both Per-Se and NDCHealth.

    About Per-Se Technologies

    Per-Se Technologies (Nasdaq: PSTI) is the leader in Connective
Healthcare. Connective Healthcare solutions from Per-Se enable
physicians and hospitals to achieve their income potential by creating
an environment that streamlines and simplifies the complex
administrative burden of providing healthcare.
    Per-Se's Connective Healthcare solutions help reduce
administrative expenses, increase revenue and accelerate the movement
of funds to benefit providers, payers and patients. More information
about Alpharetta, Georgia-based Per-Se is available at www.per-se.com.

    Safe Harbor Statement

    This Press Release contains statements that constitute
forward-looking statements within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this Press Release include the intent, belief
or current expectations of Per-Se Technologies and members of its
management team with respect to the expected closing timing of the
transaction.
    Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance, and involve risks
and uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. Important
factors that could cause actual results to differ materially from
those contemplated by the forward-looking statements in this Press
Release include, but are not limited to, failure to raise the
necessary debt financing to fund the transaction, adverse developments
with respect to the operation or performance of the respective
company's business units, adverse developments with respect to the
market price of Per-Se Technologies' common stock, failure by either
company to obtain the required shareholder or regulatory approvals, or
other failures to close the transaction. Additional factors that could
cause actual results to differ materially from those contemplated
within this Press Release can also be found in the reports filed with
the Securities and Exchange Commission (the "SEC") by Per-Se
Technologies, which are available at www.sec.gov. Per-Se Technologies
disclaims any responsibility to update any forward-looking statements.

    Important Legal Information

    This communication is being made in respect of the proposed
acquisition transaction involving Per-Se Technologies and NDCHealth
Corporation. This press release shall not constitute an offer of any
securities for sale. In connection with the proposed transaction,
Per-Se Technologies has filed with the SEC a registration statement on
Form S-4 containing a preliminary joint proxy statement/prospectus for
its shareholders and for the shareholders of NDCHealth. Per-Se has
filed other documents regarding the proposed transaction with the SEC
as well and will continue to do so in the future. Before making any
voting or investment decision, investors are urged to read the
preliminary joint proxy statement/prospectus regarding the proposed
transaction and any other relevant documents carefully in their
entirety when they become available, as well as any amendments and
supplements thereto, as they will contain important information about
the proposed transaction. The final joint proxy statement/prospectus
will be mailed to the shareholders of both NDCHealth and Per-Se.
    You may obtain copies of all documents filed with the SEC
regarding this transaction, free of charge, at the SEC's website
(www.sec.gov). You may also obtain these documents, free of charge,
from Per-Se's website (www.per-se.com) under the tab "Investors"
through the "SEC Filing" link.

    Participants in This Transaction

    Per-Se Technologies and NDCHealth and their respective directors
and executive officers may be deemed participants in the solicitation
of proxies from stockholders in connection with this transaction.
Information about the directors and executive officers of Per-Se
Technologies and NDCHealth and information about other persons who may
be deemed participants in this transaction can be found or referenced
in the preliminary joint proxy statement/prospectus. You also can find
information about Per-Se Technologies' executive officers and
directors in Per-Se's definitive proxy statement filed with the SEC on
March 25, 2005. You can find information about NDCHealth's executive
officers and directors in NDCHealth's Form 10-K/A filed with the SEC
on September 14, 2005.
    Editor's note: Per-Se Technologies is a registered trademark of
Per-Se Technologies, Inc. All other trademarks are the property of
their respective owners.

    CONTACT: Per-Se Technologies, Alpharetta
             Michele Howard, 770/237-7827
             investors@per-se.com